Primary Care Clinicians Attitudes and Knowledge of Pharmacogenetics in a Large, Multi-state, Healthcare System by Olander, Megan et al.
Student Project PHARMACY PRACTICE 
 
http://z.umn.edu/INNOVATIONS                       2018, Vol. 9, No. 2, Article 6                     INNOVATIONS in pharmacy 
                                                                             DOI: https://doi.org/10.24926/iip.v9i2.970 
1 
 
Primary Care Clinicians Attitudes and Knowledge of Pharmacogenetics in a Large, Multi-state, 
Healthcare System  
Megan Olander BS1; Stephen Waring DVM, PhD2; David D. Stenehjem, PharmD, BCOP1; Allise Taran, MPH2;                                            
Paul Ranelli PhD, MS1; Jacob T. Brown PharmD, MS1 
1College of Pharmacy University of Minnesota; 2Essentia Health 
 
Abstract 
Background: Considerable progress has been made in the way of pharmacogenetic research and the development of clinical 
recommendations; however, its implementation into clinical practice has been slower than anticipated. We sought to better understand 
its lack of clinical uptake within primary care. Aim: The primary objective of this survey was to ascertain primary care clinicians’ 
perceptions of pharmacogenetic use and implementation in an integrated health system of metropolitan and rural settings across 
several states. Methods: Primary care clinicians (including MDs, DOs, NPs, and PAs) were invited to participate in a survey via email. 
Questions about pharmacogenetics knowledge and perceptions were presented to assess current understanding and usage of 
pharmacogenetics in practice. Results: The rate of response for the survey was 17%. Of the 90 respondents, 58% were female, 69% 
were MDs/DOs, 20% were NPs, and 11% were PAs. Fifty-eight percent of respondents received their clinical degree in or after 2000. 
Ninety percent of respondents noted that they were uncomfortable ordering a pharmacogenetics test, with 76% stating they were 
uncomfortable applying the results of a pharmacogenetic test. Notably, 78% of respondents were interested in having 
pharmacogenetic testing available through Medication Therapy Management (MTM) services, although PAs were significantly less 
interested as compared to NPs and MD/DOs. Ninety-five percent of respondents were interested in a clinical decision support tool 
relevant to pharmacogenetic results. Conclusions: As a whole, prescribing clinicians in primary care clinics are uncomfortable in the 
ordering, interpreting, and applying pharmacogenetic results to individual patients. However, favorable attitudes towards providing 
pharmacogenetic testing through existing MTM clinics provides the opportunity for pharmacists to advance existing practices. 
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Introduction  
Over the past two decades pharmacogenetics has seen 
considerable growth in both research and clinical applications. 
Pharmacogenetics is the study of how pharmacokinetic and 
pharmacodynamic genes impact an individual’s ability to 
metabolize and/or respond to specific medications, and thus 
allows clinicians an additional tool when prescribing 
medications by increasing the likelihood of clinical response 
while also reducing the risk of an adverse drug event in the 
individual patient.1 In the United States alone, nearly 1 in 5 
medications dispensed have actionable recommendations 
found within the package insert.2  
 
Several surveys have assessed clinician’s knowledge, 
perceptions, and attitudes towards pharmacogenetics;3 
however, few have included rural and non-metropolitan areas. 
While the majority of physicians agree that a patient’s genetic 
profile may influence their response to drug therapy, early 
adopters of pharmacogenetic testing are limited.4 This slow 
adoption of pharmacogenetic testing may be due to limited 
educational opportunities for prescribing clinicians, as a 2012 
study showed that only 14.7% of physicians received instruction 
on pharmacogenetics during medical school, while only 23%  
 
Corresponding author: Jacob T. Brown PharmD, MS 
College of Pharmacy University of Minnesota  
Email: jtbrown@d.umn.edu  
reported pharmacogenetic training during postgraduate 
medical training.4 Surveys of predominantly urban hospitals 
and clinics have also shown that most clinicians in the United 
States do not feel comfortable ordering, interpreting, or 
applying pharmacogenetic test results in their patients.5 
 
In rural and metropolitan areas there are known differences in 
population health, such as mortality rates, number of 
individuals insured, death by motor vehicle accident, and 
patient reported health status.6,7 Additionally, there are 
substantial differences in health outcomes based on levels of 
urbanization, especially with cerebrovascular disease.6 
According to the County Health Rankings of Minnesota, rural 
areas of the state have the lowest health outcomes, including 
the lowest frequency of diabetes monitoring, highest frequency 
of preventable hospital stays, lowest access to mental health 
providers, and highest smoking rates. Precluding these areas 
from pharmacogenetic testing may worsen already existing 
health disparities. Many pharmacists are trained in these 
disciplines, and may have the opportunity to play a greater role 
in patient health outcomes in rural areas by providing 
individualized precision care to patients.  
 
Currently, widespread pharmacogenetic testing is limited to 
large healthcare institutions; however, pharmacists are well 
positioned to take the lead on implementation and application 
within their respective practice setting. The American Society 
of Health System Pharmacists recently released a statement 
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advocating for pharmacists to take the lead on the clinical 
application of pharmacogenetics.8 
 
The primary objective of this survey was to compare attitudes 
and perceptions of prescribing clinicians between metropolitan 
and non-metropolitan practice settings. Secondary objectives 
included comparing responses between types of clinicians (i.e. 
Medical Doctors (MDs)/Doctors of Osteopathy (DOs) as 
compared to Physician Assistants (PAs) or Nurse Practitioners 
(NPs)) and year of graduation.  
 
Methods 
Development of survey 
Questions were developed independently by the study team 
with the goal of describing prescribing clinician’s knowledge, 
comfort, and attitudes of pharmacogenetics in clinical practice. 
The survey consisted of questions related to demographics and 
pharmacogenetics knowledge as presented in Table 1. A full 
version of the survey can be found as a part of the supplemental 
materials. Demographics of gender, clinical degree, specialty, 
year of graduation with clinical degree, and current practice site 
were self-reported.  
 
Sampling methods 
The survey was approved by the local Institutional Review 
Board (EIRH-17-1614) and sent to 520 primary care providers in 
the Essentia Health system that included primary care 
physicians (MDs and DOs) and advanced practitioners (NPs and 
PAs). E-mail addresses were confirmed by the study 
coordinator. An email was sent to primary care providers by the 
director of primary care describing the survey’s purpose and 
providing a link to access the survey questions through REDCap.  
Completion of the survey was voluntary with no compensation. 
Participants could choose to skip questions or stop the survey 
at any time. Two reminder emails were sent out to those who 
did not complete the survey. REDCap generated a participant 
ID for each respondent in order to keep responses anonymous.  
 
This survey was conducted through Essentia Health, which is an 
integrated, not for profit, 501(c)(3) integrated healthcare 
delivery system with facilities in 4 states: Minnesota, 
Wisconsin, North Dakota and Idaho. Essentia has 15 hospitals, 
75 clinics, and more than 1,900 physicians and credentialed 
practitioners that provide more than 1.6 million patient 
encounters annually.  The Essentia service area includes 63 
counties covering over 61,000 sq. miles with over 1 million 
residents. Over 80% of Essentia’s geographical service area is 
rural and the majority of outpatient clinics (66%) are located in 
small towns and rural communities.  Essentia Health cares for 
more than 400,000 individuals seeking primary care services 
(Family Medicine, Internal Medicine and Pediatrics).  
 
 
 
Data analysis 
Based on census data from 2010, clinics were stratified based 
on Rural Urban Commuting Area (RUCA) codes for the clinic zip 
codes. The Federal Financial Institutions Examination Council 
Geocoding and Mapping system from the WWAMI Rural 
Research Center was used to determine the State-County-Tract 
FIPS Code for each clinic. A database then associated each 
State-County-Tract code with a RUCA code. The definitions of 
each are as follows: 
 
1: Metropolitan area core: primary flow within an urbanized 
area (UA) 
2: Metropolitan area high commuting: primary flow 30% or 
more to a UA 
3: Metropolitan area low commuting: primary flow 10% to 
30% to a UA 
4: Micropolitan area core: primary flow within an Urban 
Cluster of 10,000 to 49,999 (large UC) 
5: Micropolitan high commuting: primary flow 30% or more 
to a large UC 
6: Micropolitan low commuting: primary flow 10% to 30% to 
a large UC 
7: Small town core: primary flow within an Urban Cluster of 
2,500 to 9,999 (small UC) 
8: Small town high commuting: primary flow 30% or more to 
a small UC 
9: Small town low commuting: primary flow 10% to 30% to a 
small UC 
10: Rural areas: primary flow to a tract outside a UA or US                                                                                                                            
 
Primary RUCA codes were used to determine if the clinic was in 
a metropolitan area (code 1-3), micropolitan area (codes 4-6), 
small town (codes 7-9), or rural area (code 10). 
 
Statistical Analysis 
Response frequencies were calculated for all variables of the 
survey. Responses were omitted if less than 50% of the 
questionnaire was completed.  Analysis was completed using 
chi-squared tests to look at differences in groups categorized by 
RUCA scores and clinical degree. Statistical significance was 
evaluated using 95% confidence intervals with significance 
defined as p-values <0.05. Statistical analyses were performed 
using JMP Pro 13 (SAS Institute, Cary, NC).  
 
Results 
A total of 520 eligible clinicians were surveyed, with 90 
responses received (17% response rate). Fifty percent of the 
respondents were female, 59% were MDs, and 27% completed 
their clinical degree in or after 2010. Of the practice sites 
surveyed, 41% were in a metropolitan area, 19% in a 
micropolitan area, 24% from a small town, and 16% from a rural 
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area (Table 2). Figure 1 shows the geographic distribution of 
clinic responses based on RUCA score of the clinic zip code.  
 
Response rates to the knowledge based and perception based 
questions are listed in Table 3. Regarding the use of 
pharmacogenetic resources, 59% of respondents would look at 
3 or more sources, 15% at 2 sources, and 26% at a single source. 
Thirty-five percent believe that pharmacogenetic testing should 
be implemented in current practice, while 63% of respondents 
agreed that pharmacogenetic testing will soon become a 
valuable tool to predict the risk of adverse events and the 
likelihood of effectiveness with commonly used medications. 
Most providers stated that they were uncomfortable ordering 
(82%) and applying (71%) pharmacogenetic test results. 
 
Results were stratified based on RUCA scores of metropolitan 
versus non-metropolitan (micropolitan, small town, and rural), 
clinical degree, and year of graduation. No significant 
differences were found between year of graduation and survey 
responses. When comparing metropolitan clinic sites to non-
metropolitan sites, metropolitan sites were significantly more 
comfortable ordering pharmacogenetic tests (p=0.045). When 
examining interest in a clinical decision support (CDS) tool, 
there were significant differences between MD, NP, and PA, 
with PAs expressing the lowest interest (p=0.01).  There was 
also a significant difference (p=0.03) between clinical degree 
and interest in pharmacogenetics being housed in medication 
therapy management (MTM), where again PAs were the least 
interested and NPs were the most interested in 
pharmacogenetics being a part of MTM services (Table 3).  
Open ended responses from providers were predominantly 
related to concerns around cost/insurance coverage, evidence 
and benefits of the testing, improvement upon current 
guidelines, and additional education related to 
pharmacogenetics. 
 
Discussion 
This survey of primary care clinicians in a large, multi-state 
health care system showed support for the use of 
pharmacogenetics in practice while revealing concerns related 
to cost and insurance coverage, evidence and benefits of the 
tests, and a lack of general knowledge of pharmacogenetics. 
Most notable was the enthusiastic support of incorporating 
pharmacogenetic testing into existing MTM practices in 
addition to a CDS tool.  
 
Other than a greater level of comfort ordering 
pharmacogenetic tests in rural clinics, results from this survey 
did not show notably different attitudes surrounding 
pharmacogenetics between rural and metropolitan areas. 
Similar to our results, a previous survey of healthcare providers 
in rural Montana revealed optimism for pharmacogenetic 
testing, but also noted concerns related to the turnaround time 
of genetic tests, availability of a genetics specialist, and 
acceptability of genetic tests in rural populations.3 Essentia 
Health is well positioned to provide pharmacogenetic services 
to rural areas given their broad rural network and availability of 
MTM pharmacists in these locations. 
 
Currently, MTM practices have allowed pharmacists to assume 
a more active role within primary care.9 Pharmacists meet one-
on-one with patients for a consult on their medication 
experience to optimize drug therapy and improve outcomes for 
patients. Nearly 75% of respondents of this survey indicated 
they would like to see pharmacogenetic testing made available 
within MTM services. Essentia Health has 17 clinic sites in 
Minnesota that offer MTM as a complement to other primary 
care services, therefore it may be a reasonable place for 
pharmacogenetic testing and counseling to take place. Notably, 
rural pharmacies have a higher rate of MTM services than 
metropolitan areas, which may provide an ideal framework into 
which pharmacogenetics could be implemented.10 
 
CDS tools and best practice alerts within the electronic medical 
record could also help implement pharmacogenetic testing 
across a large healthcare system. As shown by Caraballo et al, 
these tools can be extremely useful in preventing adverse drug 
reactions related to pharmacogenetics.11 Nearly 90% of 
clinicians supported having a CDS tool to alert them to potential 
drug-gene interactions, considerably greater than a previous 
study where just 40% said being prompted by an alert within 
the EMR was of major importance.5 CDS tools may also be 
useful in discerning when to order pharmacogenetic testing and 
how to interpret and apply those results.12 Given the 
overwhelmingly low levels of comfort around ordering and 
interpreting pharmacogenetic tests within this survey, guidance 
from pharmacists and CDS tools could improve these aspects 
for clinicians.  
 
In order to effectively deliver pharmacogenetic information, an 
integrated healthcare team is needed. Pharmacists are the 
experts in medication management and those with an 
understanding of how genetic differences impact therapeutic 
outcomes are well positioned to recommend and interpret 
pharmacogenetic testing. Additionally, since 2016 the 
Accreditation Council for Pharmacy Education has required 
pharmacogenetics as part of the standard didactic curriculum,13 
uniquely positioning pharmacists within the healthcare team to 
take the lead on such efforts. Based on the survey results, about 
1 in 5 clinicians would contact genetic counseling for 
interpretation of pharmacogenetic test results, 11% would 
contact pharmacy, and only 1% would contact both. This 
presents an interprofessional opportunity for pharmacists to 
work with genetic counselors who are skilled in discussing the 
genetic basis of disease and how results are best shared with 
individuals and family members.14 Lack of agreement between 
clinicians on who should interpret and communicate 
pharmacogenetic test results may lead to some patient’s needs 
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going unmet.5 Increased clarity of the expertise that each 
individual on the healthcare team has with pharmacogenetics 
and who will provide interpretation of results is needed. 
Establishing pharmacists as the primary clinician ordering, 
interpreting, and applying pharmacogenetic results would 
standardize the process and could result in improved patient 
care.  
 
Physicians and advanced practitioners had some differing views 
on the implementation of pharmacogenetic testing, most 
notably the resistance seen with PAs. The reason for this 
resistance is not clear but it could stem from a lack of 
understanding of the role pharmacists can play in supporting 
the implementation of pharmacogenetic testing and the role of 
pharmacists on the health care team. The lack of interest 
observed may be similar in nature to the working relationship 
between pharmacists and physicians, where recent studies 
have shown that some physicians lack a clear understanding of 
pharmacists roles in primary health care and their training 
received in school.15  While the same may be true for PAs, 
midlevel practitioners have positive attitudes towards 
pharmacists in discussing adverse drug reactions and risk 
benefit information. Additionally, both physicians and midlevel 
practitioners had positive responses for pharmacists being 
consulted on decision making processes for optimizing a 
patient’s drug therapy.16 Future studies are needed to fully 
understand why all clinicians do not have the same positive 
view on pharmacogenetic testing but utilize pharmacists in 
other ways.  
 
Implementing pharmacogenetics into clinical practice presents 
specific challenges. Most notably these include the availability 
of tests, timeliness of test results, integrating results into the 
electronic medical record, and standardizing how 
pharmacogenetic results are applied in practice. Since there is 
not currently a standardized return of results, multiple tests 
from different commercial companies may be completed on 
the same individual with differing recommendations.17 
Additionally, there is limited availability of evidence for cost 
effectiveness of pharmacogenetic testing, making 
reimbursement variable and slowing implementation.18 More 
research into cost effectiveness of pharmacogenetic testing 
could lead to widespread implementation within hospital 
systems as they would be preventing unneeded hospital stays, 
clinic visits, and drug costs.  
 
This study has several limitations. First, the relatively low 
response rate may have affected the results due to response 
bias. Second, the majority of respondents were from a 
metropolitan area, and not all clinics in the health care system 
are represented. Lastly, while this was a multi-state survey it 
was limited to a single health system with ingrained pharmacy 
services readily available, and thus may be limited in its 
comparability to other health systems.  
This survey shows that although prescribing clinicians are 
interested in pharmacogenetic testing, additional education is 
needed prior to widespread implementation. Importantly for 
pharmacists, widespread agreement for pharmacogenetics to 
be made available within existing MTM practices in addition to 
a CDS tool provides great opportunity to advance the overall 
practice of pharmacy by providing individualized precision care 
to patients.  
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Table 1. Provider Survey Questions 
General Knowledge Questions 
At their annual physical, a patient brings a copy of their results from a direct-to-consumer pharmacogenetic 
testing service and asks you to help them understand the results.  
1. Which course of action describes what you would do? (select all that apply)  
○ Provide an interpretation based on your knowledge of certain genetic risks 
○ Refer the patient to genetics counseling 
○ Contact pharmacy for interpretation 
○ Other (please specify)  
2. Which sources would you consult when interpreting the results? (please select all that apply) 
○ Scientific literature 
○ Medical association meetings/guidelines/recommendations 
○ Drug resources (e.g. Lexi-comp, Micromedex, etc.) 
○ Internet (e.g. MayoClinic, WebMD, PharmGKB, etc.) 
○ Drug labeling/ FDA website 
○ Pharmacy 
○ Colleague 
○ Other (Please specify) 
3. How would you document their test result information? (all that apply) 
○ Enter notes into the EHR 
○ Scan document into medical records 
○ Unsure what to do with the results 
○ Other (please specify) 
Pharmacogenetic Perception Based Questions 
4. Pharmacogenetics testing will soon become a valuable tool to predict the risk of adverse events and the 
likelihood of effectiveness with commonly used medications. 
○ Agree  
○ Somewhat agree 
○ Somewhat disagree 
○ Disagree 
○ Depends on the evidence-based protocol of each drug 
5. Do you think pharmacogenetic testing should be implemented in current practices?  
○ Yes 
○ No 
○ Need more information 
          
6. What additional information would be most valuable to you? 
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7. How comfortable are you ordering pharmacogenetic testing for your patients?  
○ Very comfortable  
○ somewhat comfortable 
○ somewhat uncomfortable 
○ Very uncomfortable 
○ Not applicable 
8. How comfortable are you applying pharmacogenetic testing for your patients?  
○ Very comfortable  
○ somewhat comfortable 
○ somewhat uncomfortable 
○ Very uncomfortable 
○ Not applicable 
9. Essentia Health offers Medication Therapy Management (MTM) services to all patients. How interested are 
you in making pharmacogenetic testing available through Essentia’s current MTM program?  
○ Very interested 
○ Somewhat interested 
○ Somewhat not interested 
○ Not interested 
○ Not applicable 
10. Would you want a decision support tool to alert you to potential drug-gene interactions in patients with 
pharmacogenetic results?  
○ Very interested 
○ Somewhat interested 
○ Somewhat not interested 
○ Not interested 
11.  Is there anything else you’d like us to know about this topic?  
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Table 2. Demographics of Survey Respondents 
Categories N (%) 
Gender    
   Female 45 (58) 
   Male 31 (34) 
   Other 2 (2) 
   No response 12 (13) 
Clinical Degree   
   Medical Doctor (MD) 52 (58) 
   Doctor of Osteopathic Medicine (DO) 5 (6) 
   Physician Assistant (PA-C) 9 (1) 
   Nurse Practitioner (NP/CNP) 17 (19) 
   No response 7 (8) 
Year of Graduation with Clinical Degree   
   2010-2016 24 (27) 
   2000-2009 18 (20) 
   1990-1999 13 (14) 
   1980-1989 8 (9) 
   Before 1980 10 (11) 
   No response 17 (19) 
Current Practice Site RUCA score   
   Metropolitan (1-3) 31 (34) 
   Micropolitan (4-6) 14 (16) 
   Small town (7-9) 18 (20) 
   Rural (10) 12 (13) 
   No response 15 (17) 
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Table 3. Summary of Responses to General Knowledge and Perception Based Questions 
 
General Knowledge Questions (select all that apply)  N (%) 
At their annual physical, a patient brings a copy of their results from a direct-to-consumer pharmacogenetic testing 
service and asks you to help them understand the results.  
      1. Which course of action describes what you would do? (select all that apply)*  
• Provide an interpretation based on knowledge of certain genetic risks 52 (45) 
• Refer the patient to genetic counseling 36 (31) 
• Contact pharmacy for interpretation 18 (16) 
• Other 9 (8) 
2. Which sources would you consult when interpreting the results? (select all that apply)*  
• Scientific Literature 58 (22) 
• Medical association meetings/guidelines/recommendations 43 (16) 
• Drug resources (e.g. Lexi-comp, Micromedex, etc.) 39 (15) 
• Internet (e.g. MayoClinic, WebMD, PharmGKB, etc.) 39 (15) 
• Drug labeling/ FDA website 11 (4) 
• Pharmacy 36 (13) 
• Colleague 38 14) 
• Other (Please specify) 3 (1) 
3. How would you document their test result information? (select all that apply)*   
• Enter notes into Electronic Health Record 46 (34) 
• Scan document into medical records 77 (56) 
• Unsure what to do with results 12 (9) 
• Other 2 (1) 
Pharmacogenetic Perception Based Questions N (%) 
4. Pharmacogenetic testing will soon become a valuable tool to predict the risk of adverse events 
and the likelihood of effectiveness with commonly used medications. 
  
• Agree 27 (30) 
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• Somewhat agree 30 (33) 
• Somewhat disagree 6 (7) 
• Disagree 0 (0) 
• Depends on the evidence-based protocol of each drug 20 (22) 
• No response 7 (8) 
5. Do you think pharmacogenetics testing should be implemented in current practices?    
• Yes 32 (35) 
• No 2 (2) 
• Need more information 49 (54) 
• No response 7 (8) 
6. How comfortable are you ordering pharmacogenetic     testing for your patients?   
• Very comfortable 1 (1) 
• Somewhat comfortable 7 (8) 
• Somewhat uncomfortable 22 (24) 
• Very uncomfortable 52 (58) 
• No response 8 (9) 
7. How comfortable are you applying pharmacogenetic testing for your patients?    
• Very comfortable 2 (2) 
• Somewhat comfortable 17 (18) 
• Somewhat uncomfortable 31 (34) 
• Very uncomfortable 33 (37) 
• No response 7 (8) 
 
8. Essentia Health offers Medication Therapy Management (MTM) services to all patients. How 
interested are you in making pharmacogenetic testing available through Essentia’s current 
MTM program?  
 
• Very interested 24 (27) 
• Somewhat interested 41 (46) 
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• Somewhat uninterested 13 (14) 
• Not interested 6 (7) 
9. Would you want a decision support tool to alert you to potential drug-gene interactions in 
patients with pharmacogenetic results 
  
• Very interested 44 (49) 
• Somewhat interested 35 (39) 
• Somewhat uninterested 4 (4) 
• Not interested 0 (0) 
• No response 7 (8) 
     *These categories are not mutually exclusive.  
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Figure 1. Multi-state Practice Sites Coded Based on the RUCA Score of their Zip Code. 
 
 
 
 
 
 
 
